RHO

Chr 3ADAR

rhodopsin

Also known as: CSNBAD1, OPN2, RP4

The protein encoded by this gene is found in rod cells in the back of the eye and is essential for vision in low-light conditions. The encoded protein binds to 11-cis retinal and is activated when light hits the retinal molecule. Defects in this gene are a cause of congenital stationary night blindness. [provided by RefSeq, Aug 2017]

OMIMResearchGenerating clinical summary…
MultiplemechanismAD/ARLOEUF 1.083 OMIM phenotypes
Clinical SummaryRHO
🧬
Gene-Disease Validity (ClinGen)
RHO-related retinopathy · SDDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
200 unique Pathogenic / Likely Pathogenic· 269 VUS of 664 total submissions
💊
Clinical Trials
11 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.08LOEUF
pLI 0.000
Z-score 1.35
OE 0.60 (0.351.08)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
0.24Z-score
OE missense 0.95 (0.851.07)
209 obs / 219.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.60 (0.351.08)
00.351.4
Missense OE?0.95 (0.851.07)
00.61.4
Synonymous OE?1.17
01.21.6
LoF obs/exp: 8 / 13.3Missense obs/exp: 209 / 219.1Syn Z: -1.35
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveRHO-related retinitis pigmentosaLOFAR
definitiveRHO-related retinitis pigmentosaDNAD
definitiveRHO-related night blindness, congenital stationaryOTHERAD

This gene — mechanism propensity

DN
0.80top 25%
GOF
0.81top 10%
LOF
0.2190th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median · 1 literature citation · 73% of P/LP are missense
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFAlthough there have been significant advances in gene therapy for inherited retinal diseases, treating RHO-adRP presents a unique challenge since it is an autosomal dominant disease caused by more than 150 gain-of-function mutations in the RHO gene, rendering the established gene supplementation str1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 32882181

ClinVar Variant Classifications

664 submitted variants in ClinVar

Classification Summary

Pathogenic86
Likely Pathogenic114
VUS269
Likely Benign127
Benign21
Conflicting46
86
Pathogenic
114
Likely Pathogenic
269
VUS
127
Likely Benign
21
Benign
46
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
27
59
0
0
86
Likely Pathogenic
28
86
0
0
114
VUS
7
213
41
8
269
Likely Benign
0
5
35
87
127
Benign
0
2
16
3
21
Conflicting
46
Total623659298663

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

9 pathogenic / likely-pathogenic (of 13) ClinVar copy-number / structural variants overlap RHO — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

RHO · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Retinitis Pigmentosa

Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa

ACTIVE NOT RECRUITING
NCT06323772University Hospital TuebingenStarted 2023-11-17
Retinitis Pigmentosa

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

ACTIVE NOT RECRUITING
NCT06388200Phase PHASE3OcugenStarted 2024-06-18
Sub-Retinal Administration of OCU400-301
Retinitis PigmentosaLeber Congenital Amaurosis

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis

ACTIVE NOT RECRUITING
NCT05203939Phase PHASE1, PHASE2OcugenStarted 2022-01-24
OCU400 Low DoseOCU400 Med DoseOCU400 High Dose
Breast CancerBreast NeoplasmBreast Cancer Stage IV

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

RECRUITING
NCT06075810Phase PHASE1MBQ PharmaStarted 2023-11-09
MBQ-167
Metastatic Endometrial CarcinomaRecurrent Endometrial AdenocarcinomaRecurrent Endometrial Carcinoma

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

ACTIVE NOT RECRUITING
NCT03120624Phase PHASE1Mayo ClinicStarted 2017-09-15
BiopsyComputed TomographyFluorine F 18 Tetrafluoroborate
Autosomal Dominant Retinitis PigmentosaEye DiseasesEye Diseases, Hereditary

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

ACTIVE NOT RECRUITING
NCT04123626Phase PHASE1, PHASE2ProQR TherapeuticsStarted 2019-10-07
QR-1123Sham procedure
B-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic Syndrome

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

RECRUITING
NCT03017820Phase PHASE1Mayo ClinicStarted 2017-04-04
Biopsy ProcedureBiospecimen CollectionBone Marrow Biopsy
Retinitis Pigmentosa

Promising ROd-cone DYstrophy Gene therapY

ACTIVE NOT RECRUITING
NCT05748873Phase PHASE1, PHASE2SparingVisionStarted 2023-04-12
SPVN06
Retinitis Pigmentosa

Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

RECRUITING
NCT06952842Phase PHASE1, PHASE2Chigenovo Co., LtdStarted 2025-08-04
ZVS203e
Primary Open-Angle Glaucoma (POAG)

GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma

RECRUITING
NCT06921317Phase PHASE1, PHASE2IVIEW Therapeutics Inc.Started 2025-11-19
GVB-2001-high doseGVB-2001-low dose
Retinitis Pigmentosa

Prospective Natural History Study of Retinitis Pigmentosa

ACTIVE NOT RECRUITING
NCT04285398Phase NASparingVisionStarted 2020-02-12
Ophthalmic examinationsMobility Test